https://scholars.lib.ntu.edu.tw/handle/123456789/535937
標題: | Comparison of flomoxef with latamoxef in the treatment of sepsis and/or gram-negative bacteremia in adult patients | 作者: | YEE-CHUN CHEN CHIEN-CHING HUNG Lin S.-F. SHAN-CHWEN CHANG Hsieh W.-C. |
公開日期: | 1996 | 出版社: | Elsevier B.V. | 卷: | 7 | 期: | 1 | 起(迄)頁: | 69-74 | 來源出版物: | International Journal of Antimicrobial Agents | 摘要: | The safety and efficacy of flomoxef and latamoxef were compared in the treatment of hospitalized patients with sepsis and/or Gram-negative bacteremia in a prospective, open-labelled clinical trial. Patients were randomized to receive 1 to 2 g intravenous doses of either flomoxef every 6 to 12 h, or latamoxef every 8 to 12 h. Data from 21 patients given flomoxef and 23 patients given latamoxef were included in the evaluation of efficacy. Flomoxef produced clinical cure and satisfactory microbiological responses in 85.7% and 100% of patients, respectively. These results were similar to those obtained with latamoxef (87% and 100%, respectively). In addition, no significant difference was found in mean age, sex, severity of infection, distribution of pathogens and focus of infection between the two groups. However, the flomoxef group included more patients with ultimately fatal diseases. Six patients given flomoxef and two patients given latamoxef developed superinfections caused by yeast, enterococci and Pseudomonas aeruginosa in the urinary tract. Mild and reversible adverse reactions probably related to flomoxef and latamoxef were noted in 14.3% and 13% of patients, respectively. The results of this study demonstrated that flomoxef is a safe and effective antimicrobial agent in the treatment of patients with sepsis and/or Gram-negative bacteremia. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0029975588&doi=10.1016%2f0924-8579%2896%2900013-1&partnerID=40&md5=d1cfebe4e2bfcfe6cac277bfbe5e40c3 https://scholars.lib.ntu.edu.tw/handle/123456789/535937 |
ISSN: | 0924-8579 | DOI: | 10.1016/0924-8579(96)00013-1 | SDG/關鍵字: | amikacin; ampicillin; cefazolin; cefmetazole; cefotaxime; cefoxitin; flomoxef; gentamicin; latamoxef; piperacillin; tobramycin; adolescent; adult; aged; antibiotic sensitivity; antibiotic therapy; article; bacteremia; clinical article; clinical trial; controlled clinical trial; controlled study; drug efficacy; drug safety; female; Gram negative infection; human; intravenous drug administration; liver toxicity; male; minimum inhibitory concentration; nephrotoxicity; priority journal; Pseudomonas aeruginosa; randomized controlled trial; rash; sepsis; treatment outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。